flutiform offers sustained anti-inflammatory power1

Fluticasone propionate is a potent corticosteroid with sustained anti-inflammatory activity.1–3 It binds to glucocorticoid receptors within cells and decreases the release of inflammatory mediators from immune cells.4

Flutiform-HCP power MOA video.jpg

flutiform helps reduce asthma exacerbations5

Pooled analysis from 5 double-blind studies (8–12 weeks; flutiform 50/5, 125/5 and 250/10 μg vs. FP 50, 125 and 250 μg 2 puffs b.i.d).5 FP: fluticasone propionate; b.i.d: twice daily.

flutiform significantly reduces asthma exacerbations* vs. fluticasone propionate.In addition, two open-label, long-term studies showed that only 2.1% of patients taking flutiform experienced an exacerbation requiring oral corticosteroids.6

*Exacerbation defined as peak expiratory flow rate >30% below baseline ≥2 consecutive days, awakening at night due to asthma ≥2 consecutive days, rescue medication use at least 4–5 times/day ≥2 consecutive days, deterioration in asthma necessitating additional therapy, or emergency visit/hospitalisation due to asthma.

n=752 patients, Study 1: 60 weeks, Study 2: up to 52 weeks duration. Pooled analysis.





1. flutiform Summary of Product Characteristics 2015. 2. Mager DE et al. Pharm Sci. 2003; 92: 1521–1525. 3. Johnson M. J Allergy Clin Immunol. 1998; 101(4): S434S439. 4. Barnes PJ. British Journal of Pharmacology. 2006; 148(3): 245–254. 5. Papi A et al. Respir Med. 2015; 109(2): 208–217. 6. Papi A et al. J Aerosol Med Pulm Drug Deliv. 2016: 29; 346-361.

You are now leaving flutiform.com and moving to an external website independently operated and not managed by Mundipharma International Ltd. Mundipharma International Ltd assumes no responsibility for the site or its content.

If you do not wish to leave this site, click Cancel or click OK to continue.

OK Cancel